Tandem Diabetes Care Inc. (NASDAQ:TNDM) shares fell 2.9% on Wednesday . The company traded as low as $6.50 and last traded at $6.58, with a volume of 110,265 shares trading hands. The stock had previously closed at $6.78.

A number of brokerages have weighed in on TNDM. Robert W. Baird restated a “buy” rating on shares of Tandem Diabetes Care in a report on Monday, May 2nd. Piper Jaffray Cos. restated a “buy” rating and issued a $12.00 price objective on shares of Tandem Diabetes Care in a report on Thursday, April 21st. Zacks Investment Research upgraded Tandem Diabetes Care from a “hold” rating to a “buy” rating and set a $9.25 price objective on the stock in a report on Wednesday, May 4th. Wedbush restated an “outperform” rating and issued a $20.00 price objective on shares of Tandem Diabetes Care in a report on Friday, July 29th. Finally, Sterne Agee CRT restated a “neutral” rating on shares of Tandem Diabetes Care in a report on Monday, May 16th. One research analyst has rated the stock with a sell rating, three have given a hold rating and four have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of $14.21.

The stock has a 50 day moving average price of $7.38 and a 200 day moving average price of $8.10. The company’s market capitalization is $198.37 million.

Tandem Diabetes Care (NASDAQ:TNDM) last issued its quarterly earnings results on Thursday, July 28th. The medical device company reported ($0.60) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.65) by $0.05. The firm had revenue of $23 million for the quarter, compared to analyst estimates of $23.08 million. The firm’s revenue for the quarter was up 46.5% compared to the same quarter last year. During the same quarter last year, the business posted ($0.65) earnings per share. On average, analysts anticipate that Tandem Diabetes Care Inc. will post ($2.14) earnings per share for the current fiscal year.

In other news, EVP John F. Sheridan sold 15,000 shares of Tandem Diabetes Care stock in a transaction on Monday, August 1st. The stock was sold at an average price of $6.52, for a total transaction of $97,800.00. Following the transaction, the executive vice president now directly owns 22,763 shares in the company, valued at approximately $148,414.76. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

A hedge fund recently raised its stake in Tandem Diabetes Care stock. Westfield Capital Management Co. LP boosted its stake in shares of Tandem Diabetes Care Inc. (NASDAQ:TNDM) by 3.3% during the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 1,125,281 shares of the medical device company’s stock after buying an additional 35,680 shares during the period. Westfield Capital Management Co. LP owned 3.74% of Tandem Diabetes Care worth $13,290,000 at the end of the most recent quarter.

Tandem Diabetes Care, Inc is a medical device company. The Company is engaged in designing, developing and commercializing products for people with insulin-dependent diabetes. The Company manufactures and sells three insulin pump products, which include t:slim Insulin Delivery System (t:slim), t:flex Insulin Delivery System (t:flex) and t:slim G4 Insulin Delivery System (t:slim G4).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.